Dr. Roger Davis, professor of biotechnology at the University of Massachusetts, will deliver the keynote address on "Signal Transduction by Stress-Activated MAP Kinases". Two sessions will follow--one on "Extracellular Matrix, Mineralized Tissues and Human Disease," and the other on "Infection and Immunity."

The first session will be chaired by Dr. George Martin, vice president of scientific affairs at Fibrogen, and will feature Gideon A. Rodan, M.D., Ph.D., research vice president, department of bone biology and osteoporosis, Merck Research Labs; John D. Termine, Ph.D., vice president, osteoporosis, Eli Lilly & Company; and Darwin Prockop, M.D., Ph.D., director, Center for Gene Therapy, Allegheny University of the Health Sciences,

Session two will be chaired by Dr. Max D. Cooper, investigator, Howard Hughes Medical Institute, University of Alabama at Birmingham. The speakers are: Gail H. Cassell, Ph.D., vice president, infectious diseases, Eli Lilly & Company; Nina Agabian, Ph.D., professor of molecular pathogenesis, University of California at San Francisco; John J. Cebra, Ph.D., professor, Department of Biology, University of Pennsylvania; and Joost J. Oppenheim, M.D., chief, Laborary of Molecular Immunoregulation, National Cancer Institute.

The symposium is open to the entire NIH community. For further information, call 496-4261.